Profile data is unavailable for this security.
About the company
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
- Revenue in USD (TTM)0.00
- Net income in USD-179.53m
- Incorporated2013
- Employees112.00
- LocationAllovir Inc1100 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (617) 433-2605
- Fax+1 (302) 655-5049
- Websitehttps://www.allovir.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Instil Bio Inc | 0.00 | -123.32m | 82.08m | 49.00 | -- | 0.3988 | -- | -- | -18.96 | -18.96 | 0.00 | 31.65 | 0.00 | -- | -- | 0.00 | -33.63 | -- | -35.47 | -- | -- | -- | -- | -- | -- | -- | 0.2841 | -- | -- | -- | 30.06 | -- | -- | -- |
Kronos Bio Inc | 7.59m | -116.39m | 82.33m | 61.00 | -- | 0.601 | -- | 10.85 | -2.00 | -2.00 | 0.1301 | 2.28 | 0.0322 | -- | -- | 122,371.00 | -49.32 | -35.47 | -54.43 | -37.14 | -- | -- | -1,534.11 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
PMV Pharmaceuticals Inc | 0.00 | -65.10m | 82.82m | 63.00 | -- | 0.3894 | -- | -- | -1.32 | -1.32 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -26.53 | -21.16 | -27.81 | -21.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.94 | -- | 16.31 | -- |
Sangamo Therapeutics Inc | 18.76m | -328.05m | 83.27m | 405.00 | -- | 1.44 | -- | 4.44 | -1.86 | -1.86 | 0.1057 | 0.2784 | 0.0659 | -- | 4.86 | 46,311.11 | -115.20 | -26.09 | -139.17 | -31.04 | -- | -- | -1,749.06 | -136.53 | -- | -- | 0.00 | -- | 58.34 | 15.85 | -34.09 | -- | -13.25 | -- |
Bioatla Inc | 0.00 | -119.24m | 84.20m | 65.00 | -- | 1.69 | -- | -- | -2.49 | -2.49 | 0.00 | 1.03 | 0.00 | -- | -- | 0.00 | -81.18 | -48.72 | -96.07 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Benitec Biopharma Inc | 7.00k | -21.69m | 84.21m | 18.00 | -- | 2.13 | -- | 12,030.53 | -9.87 | -9.87 | 0.0031 | 4.22 | 0.0006 | -- | 0.1284 | 388.89 | -186.85 | -83.43 | -260.89 | -98.77 | 1,542.86 | 96.86 | -309,885.70 | -468.04 | -- | -307.03 | 0.00 | -- | 2.74 | -53.84 | -7.44 | -- | -56.51 | -- |
Beyondspring Inc | 1.75m | -21.03m | 85.44m | 35.00 | -- | -- | -- | 48.79 | -0.5392 | -0.5392 | 0.0449 | -0.6868 | 0.0493 | -- | -- | 48,638.89 | -61.80 | -75.50 | -88.85 | -96.48 | -- | -- | -1,253.46 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Clearside Biomedical Inc | 8.45m | -34.97m | 85.94m | 30.00 | -- | -- | -- | 10.17 | -0.543 | -0.543 | 0.1321 | -0.2919 | 0.1993 | -- | -- | 281,733.30 | -82.44 | -63.57 | -94.63 | -81.77 | 93.08 | -- | -413.72 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Leap Therapeutics Inc | 0.00 | -53.37m | 86.10m | 54.00 | -- | 1.22 | -- | -- | -2.39 | -2.39 | 0.00 | 1.85 | 0.00 | -- | -- | 0.00 | -64.88 | -80.06 | -74.25 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Allovir Inc | 0.00 | -179.53m | 89.00m | 112.00 | -- | 0.7382 | -- | -- | -1.65 | -1.65 | 0.00 | 1.05 | 0.00 | -- | -- | 0.00 | -92.50 | -52.85 | -100.98 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
Verastem Inc | 0.00 | -105.52m | 90.92m | 73.00 | -- | 3.63 | -- | -- | -4.40 | -4.40 | 0.00 | 1.83 | 0.00 | -- | -- | 0.00 | -86.34 | -62.70 | -108.04 | -75.18 | -- | -- | -- | -406.17 | -- | -- | 0.4703 | -- | -100.00 | -- | -18.36 | -- | -- | -- |
Anixa Biosciences Inc | 0.00 | -11.60m | 92.50m | 4.00 | -- | 3.92 | -- | -- | -0.3694 | -0.3694 | 0.00 | 0.7381 | 0.00 | -- | -- | 0.00 | -45.19 | -59.69 | -46.33 | -62.61 | -- | -- | -- | -6,040.10 | -- | -- | 0.00 | -- | -- | -28.36 | 27.83 | -- | -- | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -15.40m | 92.79m | 9.00 | -- | 4.70 | -- | -- | -0.1496 | -0.1496 | 0.00 | 0.1914 | 0.00 | -- | -- | 0.00 | -40.89 | -- | -50.40 | -- | -- | -- | -- | -- | -- | -2,083.71 | 0.0183 | -- | -- | -- | 34.25 | -- | -- | -- |
Assembly Biosciences Inc | 12.95m | -51.36m | 92.98m | 65.00 | -- | 2.56 | -- | 7.18 | -11.22 | -11.22 | 2.76 | 5.95 | 0.1276 | -- | 34.07 | 199,200.00 | -50.60 | -39.69 | -66.58 | -44.03 | -- | -- | -396.63 | -409.24 | -- | -- | 0.00 | -- | -- | -13.51 | 34.23 | -- | -5.59 | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 11.29m | 9.82% |
Invus Public Equities Advisors LLCas of 31 Mar 2024 | 6.60m | 5.74% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 4.20m | 3.65% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.13m | 2.72% |
Millennium Management LLCas of 31 Mar 2024 | 2.94m | 2.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.88m | 2.51% |
Irenic Capital Management LPas of 31 Mar 2024 | 2.58m | 2.24% |
Redmile Group LLCas of 31 Mar 2024 | 1.91m | 1.66% |
Acadian Asset Management LLCas of 31 Mar 2024 | 1.59m | 1.38% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.27m | 1.11% |